Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-mutated Non-small Cell Lung Cancer
Cancer Research and Treatment. 2019;51(1):408-412 
Computational methods for the analysis and prediction of drug resistance in EGFR-mutated non-small cell lung cancer patients
. 2021;
Computational methods for the analysis and prediction of drug resistance in EGFR-mutated non-small cell lung cancer patients
. 2021;
Osimertinib
Reactions Weekly. 2021;1836(1):619-619
A Case Report of Successful treatment with Crizotinib to overcome resistance to Osimertinib in an EGFR mutated non small cell lung cancer patient harboring an acquired MET Exon 14 mutation.
Clinical Lung Cancer. 2021;
Challenges in the Management of EGFR-Mutated Non-Small Cell Lung Cancer Patients with Acquired Resistance to Tyrosine Kinase Inhibitors
Oncology. 2014;87(2):83-94
REBIOPSY IN NON-SMALL CELL LUNG CANCER PATIENTS WITH ACQUIRED RESISTANCE TO EGFR-TKI
Respirology. 2017;22:242-242
Durable response to osimertinib in EGFR mutated T790M wildtype non-small cell lung cancer with leptomeningeal metastases: A case report
Lung Cancer. 2017;114:68-69
Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3 -mutation, localized transformation to EGFR -mutated SCLC, and acquired T790M EGFR -mutation
Lung Cancer. 2017;113:14-17
Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
Nature Communications. 2017;8(1):